| SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Milos PESEK, Vitezslav KOLEK, Leona KOUBKOVA, Marcela TOMÍŠKOVÁ, Jaromír ROUBEC, Libor HAVEL a František SALAJKA. The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location. In The 14th Central European Lung Cancer Congress. 2014. ISSN 2218-6751. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1218646,
author = {Skřičková, Jana and Bortlíček, Zbyněk and Hejduk, Karel and Pesek, Milos and Kolek, Vitezslav and Koubkova, Leona and Tomíšková, Marcela and Roubec, Jaromír and Havel, Libor and Salajka, František},
booktitle = {The 14th Central European Lung Cancer Congress},
keywords = {Gefitinib; NSCLC},
language = {eng},
title = {The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location},
year = {2014}
}
TY - CONF
ID - 1218646
AU - Skřičková, Jana - Bortlíček, Zbyněk - Hejduk, Karel - Pesek, Milos - Kolek, Vitezslav - Koubkova, Leona - Tomíšková, Marcela - Roubec, Jaromír - Havel, Libor - Salajka, František
PY - 2014
TI - The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location
KW - Gefitinib
KW - NSCLC
N2 - This study evaluates treatment outcomes in 127 non-small cell lung cancer (NSCLC) patients from Czech Republic according to activated mutations located in exons 19 (Del 19) and 21 (L858R).
ER -
SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Milos PESEK, Vitezslav KOLEK, Leona KOUBKOVA, Marcela TOMÍŠKOVÁ, Jaromír ROUBEC, Libor HAVEL a František SALAJKA. The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location. In \textit{The 14th Central European Lung Cancer Congress}. 2014. ISSN~2218-6751.
|
